Bromide

Bromide

SCHEMBL1726261

Br.Oc1ccc(-c2cn3cc(I)ccc3n2)cc1

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.65
RAB9A P51151 6/20 0.65
KDM4E B2RXH2 4/20 0.65
GFER P55789 3/20 0.65
APP P05067 6/20 0.64
ALDH1A1 P00352 5/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
HPGD P15428 2/20 0.60
POLB P06746 2/20 0.60
NFKB1 P19838 1/20 0.60
NFKB2 Q00653 1/20 0.60
RELA Q04206 1/20 0.60
RCE1 Q9Y256 1/20 0.60
KMT2A Q03164 2/20 0.51
PAX8 Q06710 2/20 0.51
MEN1 O00255 1/20 0.51
MITF O75030 1/20 0.51
KDM5A P29375 1/20 0.51
KDM5C P41229 1/20 0.51
ALDH1A3 P47895 6/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1726415 0.98 APP (0.66) NPC1RAB9AKDM4EGFERAPP
SCHEMBL15177306 0.88 APP (0.73) NPC1RAB9AKDM4EAPPALDH1A1
SCHEMBL2257095 0.84 APP (0.73) NPC1RAB9AKDM4EGFERAPP
SCHEMBL24320031 0.83 NPC1 (0.74) NPC1RAB9AKDM4EGFERAPP
SCHEMBL2904371 0.82 APP (0.66) NPC1RAB9AKDM4EGFERAPP
SCHEMBL26603206 0.82 APP (0.69) NPC1RAB9AKDM4EAPPALDH1A1
SCHEMBL217156 0.82 RAB9A (0.75) NPC1RAB9AKDM4EAPPALDH1A1
SCHEMBL1985593 0.82 APP (0.66) NPC1RAB9AKDM4EAPPALDH1A1
SCHEMBL6491308 0.81 ALDH1A3 (0.69) NPC1RAB9AKDM4EAPPALDH1A1
Bromide SCHEMBL1726370 0.81 APP (0.64) NPC1RAB9AKDM4EGFERAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8506930-B2 Compounds having affinity for amyloid NIHON MEDI-PHYSICS CO., LTD. (JP) 2013-08-13 US disclosed
US-8303935-B2 Alkoxy substituted imidazo[1,2-a]pyridines having affinity for amyloid NIHON MEDI-PHYSICS CO., LTD. (JP) 2012-11-06 US disclosed
US-20120271053-A1 NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID NIHON MEDI-PHYSICS CO., LTD. (JP) 2012-10-25 US disclosed
US-8207189-B2 Compound having affinity for amyloid NIHON MEDI-PHYSICS CO., LTD. (JP) 2012-06-26 US disclosed
WO-2011029443-A8 DEVICE FOR A MULTIPLE SOCKET FOR RECEIVING PLUG CONNECTIONS HOHENADEL THORSTEN (DE) 2012-05-10 WO disclosed
EP-2019103-B1 COMPOUND HAVING AFFINITY FOR AMYLOID NIHON MEDIPHYSICS CO LTD (JP) 2011-11-30 EP disclosed
EP-2098522-B1 COMPOUNDS HAVING AFFINITY FOR AMYLOID NIHON MEDIPHYSICS CO LTD (JP) 2011-10-19 EP disclosed
US-20100249419-A1 UTILIZATION OF NOVEL COMPOUNDS WITH AMYLOID AFFINITY AND METHOD OF PRODUCING THE SAME NIHON MEDI-PHYSICS CO., LTD. (JP) 2010-09-30 US disclosed
EP-2216050-A1 UTILIZATION OF NOVEL COMPOUNDS WITH AMYLOID AFFINITY AND METHOD OF PRODUCING THE SAME Nihon Medi-Physics Co., Ltd. (JP) 2010-08-11 EP disclosed
US-20100069640-A1 NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID NIHON MEDI-PHYSICS COL, LTD. (JP) 2010-03-18 US disclosed
US-20090252679-A1 Novel Compound Having Affinity for Amyloid NIHON MEDI-PHYSICS CO., LTD. (JP) 2009-10-08 US disclosed
EP-2098522-A1 NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID NIHON MEDI-PHYSICS CO., LTD. (JP) 2009-09-09 EP disclosed
EP-2019103-A1 NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID NIHON MEDI-PHYSICS CO., LTD. (JP) 2009-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069640-A1 NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID APP, APBA1, C1QBP NPC1 172/4885RAB9A 2084/4885KDM4E 3915/4885
US-20100249419-A1 UTILIZATION OF NOVEL COMPOUNDS WITH AMYLOID AFFINITY AND METHOD OF PRODUCING THE SAME APBA1, S100A4, APP NPC1 1367/4885RAB9A 3248/4885KDM4E 4116/4885
US-20090252679-A1 Novel Compound Having Affinity for Amyloid APBA1, SAAL1, SLC43A1 NPC1 412/4885RAB9A 1323/4885KDM4E 4742/4885
US-20120271053-A1 NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID APBA1, SAAL1, SLC43A1 NPC1 412/4885RAB9A 1323/4885KDM4E 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.